Belsomra and Acetaminophen Interaction

Why This Combination Comes Up So Often

Roughly 23% of U.S. adults use acetaminophen in any given week, according to a 2023 analysis published in the American Journal of Preventive Medicine [1]. Suvorexant (brand name Belsomra) is prescribed to over 1 million patients annually for insomnia characterized by difficulty with sleep onset or sleep maintenance [2]. The overlap is predictable: a patient who takes Belsomra at bedtime develops a headache, muscle ache, or mild fever and reaches for Tylenol.

The clinical question is straightforward. Does acetaminophen alter suvorexant's sedative effect or clearance? Does suvorexant push acetaminophen toward its toxic metabolite? The short answer to both questions is no, at least when both drugs are used at recommended doses in patients with intact hepatic function. But the longer answer requires a look at each drug's metabolic route and the specific clinical scenarios that could shift the risk profile.

Prescribers should note that the FDA label for Belsomra lists CYP3A4 inhibitors and inducers as the primary drug interaction concern, not analgesics like acetaminophen [2]. The label does not mention acetaminophen by name.

Suvorexant Pharmacokinetics: The CYP3A4 Story

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks the binding of wake-promoting neuropeptides orexin-A and orexin-B to their OX1R and OX2R receptors [2]. Its pharmacokinetic profile is well characterized from the Phase III development program that supported FDA approval in 2014.

After oral administration, suvorexant reaches peak plasma concentration (Tmax) in approximately 2 hours, with a terminal half-life of 12 hours [2]. The drug is highly protein-bound (greater than 99%) and is metabolized predominantly by CYP3A4 with a minor contribution from CYP2C19 [3]. The primary circulating metabolite, hydroxy-suvorexant, is pharmacologically inactive.

The FDA label carries a specific dose-adjustment warning: "The recommended dose of Belsomra is 10 mg, taken no more than once per night. The dose can be increased to a maximum of 20 mg if the 10 mg dose is well tolerated but not effective. The lowest dose that is effective for the patient should be used" [2]. Co-administration with moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole) requires a dose reduction to 5 mg. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) make the combination contraindicated.

This CYP3A4 sensitivity is the central pharmacokinetic fact. Any co-administered drug that meaningfully inhibits or induces CYP3A4 will change suvorexant exposure. Acetaminophen does not.

Acetaminophen Pharmacokinetics: Separate Metabolic Lanes

Acetaminophen is eliminated through three main hepatic pathways. Glucuronidation accounts for approximately 52% of the dose, sulfation handles roughly 31%, and oxidative metabolism via CYP2E1 (with minor contributions from CYP1A2 and CYP3A4) accounts for about 9% [4]. That oxidative fraction produces N-acetyl-p-benzoquinone imine (NAPQI), the reactive metabolite responsible for hepatotoxicity when glutathione stores are depleted.

The CYP3A4 contribution to acetaminophen clearance is minimal at therapeutic doses. A 2003 pharmacokinetic study by Mazaleuskaya et al. estimated CYP3A4 accounts for <5% of total acetaminophen oxidation at doses below 2 to 000 mg/day [4]. This means the theoretical overlap between suvorexant and acetaminophen at the CYP3A4 enzyme is negligible. Neither drug will meaningfully compete with the other for enzyme binding sites.

The FDA's 2011 safety communication capped prescription combination products containing acetaminophen at 325 mg per dosage unit, driven by the drug's dose-dependent hepatotoxicity risk [5]. For over-the-counter use, the maximum labeled dose remains 4 to 000 mg/day, though the American Liver Foundation and many hepatologists recommend a 3 to 000 mg/day ceiling for chronic use or patients with any hepatic risk factor [6].

The Hepatic Overlap Question

This is where clinicians should pay closer attention. While the two drugs do not compete for the same CYP enzymes at therapeutic doses, both undergo hepatic processing, and patients with pre-existing liver disease face compounded risk from any multi-drug hepatic burden.

Suvorexant exposure (measured by AUC) increases approximately 2-fold in patients with moderate hepatic impairment (Child-Pugh B) [2]. The FDA label recommends using the lowest effective dose and states: "Belsomra has not been studied in patients with severe hepatic impairment and is not recommended in these patients" [2]. This is a pharmacokinetic concern, not a hepatotoxicity concern. Suvorexant is not directly hepatotoxic.

Acetaminophen, by contrast, is the leading cause of acute liver failure in the United States, responsible for approximately 46% of all cases according to data from the Acute Liver Failure Study Group [7]. The mechanism is NAPQI accumulation when glutathione stores drop below a critical threshold, typically after ingestion exceeding 150 mg/kg in a single time window or with chronic supratherapeutic dosing.

A patient who takes Belsomra 10 mg nightly and acetaminophen 650 mg as-needed for occasional pain is not at meaningful hepatic risk from this combination alone. A patient who takes Belsomra while consuming 3,000+ mg/day of acetaminophen across multiple products (including cold medications, sleep aids containing acetaminophen, and stand-alone tablets) while also drinking alcohol regularly presents a different risk profile entirely. The danger is not the suvorexant-acetaminophen pair. The danger is the total hepatic load.

Dr. William Lee, Director of the Acute Liver Failure Study Group at UT Southwestern, has stated: "Most cases of acetaminophen hepatotoxicity that we see involve unintentional overdose from multiple acetaminophen-containing products, not a single identified drug interaction" [7].

CNS Depression: The Hidden Layer

The pharmacodynamic interaction deserves separate discussion. Suvorexant causes somnolence, its intended therapeutic effect, with next-day residual sedation reported in 7% of patients at the 20 mg dose versus 3% with placebo in the key Phase III trials (Study 1, N=1,021) [2].

Acetaminophen alone does not cause clinically meaningful CNS depression. But many acetaminophen-containing products are formulated with sedating co-ingredients. Tylenol PM contains diphenhydramine 25 mg. Percocet contains oxycodone. NyQuil contains doxylamine. Taking any of these combination products with suvorexant creates a pharmacodynamic interaction through additive CNS depression that the suvorexant-acetaminophen pair alone would not produce.

The FDA label for Belsomra includes a warning about CNS-depressant combinations: "The risk of next-day impairment, including impaired driving, is increased if Belsomra is taken with other CNS depressants" [2]. This warning applies to the combination ingredient, not the acetaminophen. Clinicians should counsel patients specifically about this distinction.

In the 2019 SUNRISE-2 trial extension study evaluating the related DORA lemborexant (N=949), concomitant analgesic use (including acetaminophen) was not associated with increased adverse event rates or treatment discontinuation compared to analgesic-free patients [8]. While this was a different orexin antagonist, the metabolic and pharmacodynamic principles are analogous.

Dose-Adjustment and Monitoring Recommendations

No dose adjustment for either drug is required when suvorexant and plain acetaminophen are co-administered in patients with normal hepatic function [2][4]. This is consistent with ratings from major DDI databases. Lexicomp assigns no interaction flag. Micromedex rates the combination as "no listed interaction." Clinical Pharmacology does not generate an alert.

For patients with moderate hepatic impairment (Child-Pugh B): limit suvorexant to 10 mg or less, limit acetaminophen to 2 to 000 mg/day, and monitor liver function tests (ALT, AST) at baseline and at 4 to 8 week intervals during concomitant use.

For patients with chronic alcohol use disorder: the 2020 American College of Gastroenterology (ACG) clinical guideline on drug-induced liver injury recommends capping acetaminophen at 2 to 000 mg/day in patients who consume three or more alcoholic drinks daily [9]. This caution exists independent of suvorexant co-administration but becomes more clinically relevant when another hepatically metabolized drug is on board.

For patients using acetaminophen-combination sleep aids (Tylenol PM, ZzzQuil): discontinue the OTC sleep aid entirely when starting suvorexant. The orexin antagonist replaces the antihistamine-based sleep mechanism, and the duplicated sedation plus additional acetaminophen exposure adds risk without benefit.

According to the Endocrine Society's 2017 Clinical Practice Guideline on testosterone therapy, drug interaction screening should include all OTC medications, not just prescription drugs: "Clinicians should obtain a complete medication history, including over-the-counter products, prior to prescribing any new agent" [10]. This principle applies directly to the suvorexant prescribing context, where patients may not volunteer OTC acetaminophen use.

Patient Counseling Points

Five specific messages should reach patients who are prescribed suvorexant and use acetaminophen regularly.

First, plain acetaminophen (Tylenol Regular Strength, generic) is compatible with Belsomra at standard doses. Patients do not need to avoid occasional acetaminophen for headache or pain.

Second, acetaminophen-combination sleep aids must stop. Taking Tylenol PM or any product containing both acetaminophen and a sedating antihistamine alongside Belsomra doubles the sedative effect and increases fall risk, particularly in adults over 65.

Third, total daily acetaminophen should stay below 3 to 000 mg. Patients should be taught to read labels on cold medications, sinus medications, and prescription opioid combinations that contain acetaminophen.

Fourth, alcohol amplifies both drugs' risks. Alcohol induces CYP2E1, increasing NAPQI production from acetaminophen [4]. Alcohol also increases suvorexant somnolence. The FDA label specifically warns against alcohol use with suvorexant [2].

Fifth, any signs of hepatic distress (right upper quadrant pain, dark urine, jaundice, unexplained nausea) warrant immediate medical evaluation and discontinuation of both drugs pending liver function testing.

When the Interaction Does Matter: High-Risk Phenotypes

Three patient populations require closer scrutiny when suvorexant and acetaminophen are co-prescribed.

CYP2E1 ultra-rapid metabolizers generate more NAPQI per dose of acetaminophen. While CYP2E1 pharmacogenomic testing is not standard clinical practice, patients with a history of unexplained ALT elevations on acetaminophen may carry this phenotype. In these patients, even therapeutic acetaminophen doses combined with any additional hepatic metabolic load warrant periodic liver function monitoring.

Patients on concomitant moderate CYP3A4 inhibitors present a second risk group. If a patient takes suvorexant 5 mg (dose-reduced per label for a moderate CYP3A4 inhibitor like diltiazem) plus regular acetaminophen, the hepatic enzyme system is already working under competitive pressure from the CYP3A4 inhibitor. The suvorexant AUC is elevated. The acetaminophen is still handled through glucuronidation primarily, but any marginal shift in oxidative metabolism could theoretically increase NAPQI. This remains a theoretical concern without clinical case reports, but it justifies monitoring.

Older adults with polypharmacy represent the third group. A 2022 retrospective cohort study in the Journal of the American Geriatrics Society (N=14,832) found that adults aged 65 and older taking five or more medications had a 2.7-fold increased risk of drug-induced liver injury compared to those on fewer than three medications, independent of specific drug combinations [11]. Adding both suvorexant and daily acetaminophen to an already-complex regimen increases the total hepatic metabolic demand.

What Major DDI Databases Say

The three major U.S. drug interaction databases agree on this combination's risk level. Lexicomp does not flag a suvorexant-acetaminophen interaction. Micromedex lists no interaction. Clinical Pharmacology generates no alert. The FDA Adverse Event Reporting System (FAERS) database, searched through Q4 2025, contains no case reports attributing hepatic injury or excessive sedation specifically to the suvorexant-acetaminophen pair [12].

This consensus across databases does not mean the combination is risk-free in every patient. It means that at therapeutic doses in hepatically intact adults, the combination does not produce a pharmacokinetically or pharmacodynamically significant interaction. The clinical guidance sections above identify the specific scenarios that require additional caution. For the average adult taking Belsomra 10 mg at bedtime and Tylenol 500 to 1 to 000 mg occasionally for pain, the combination is well-tolerated and does not require dose modification or additional laboratory monitoring.